Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New indication: Subcutaneous Rituximab - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New indication: Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New indication: Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma

New indication: Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma
Study:
  • Randomized, open-label phase 3 trial (LYSA)
  • Previously untreated low-burden Follicular lymphoma
  • SOC (n=102) vs. Rituximab sc (n=100)
Efficacy:
  • CR: 36.3% vs. 59.0%, p=0.001
  • 4-year PFS: 41.2% vs.58.1%, p=0.008
  • 4-year OS:95.0 vs.96.7%, p=ns
Safety:
  • Grade≥3 AEs: Lymphopenia (3.0% in both arm), injection site reaction (3.0% in both arm)

J Clin Oncol APR 18, 2023

Cartron G et al. Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study

http://doi.org/10.1200/JCO.22.02327

Reviewed by Elvin CHALABİYEV, MD on MAY 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More